Enzyme replacement therapy for pompe disease

Current Neurology and Neuroscience Reports

Volumn 12, Issue 1, 2012, Pages 70-75

  Angelini, Corrado ^a   Semplicini, Claudio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acid maltase deficiency; Enzyme replacement therapy; Glycogenosis type II; Pompe disease

Indexed keywords

ALPHA GLUCOSIDASE; GLUCOSE; GLYCOGEN; IMMUNOGLOBULIN; LYSOSOME ENZYME; METHOTREXATE; PLACEBO; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB;

AEROBIC EXERCISE; ARTICLE; ARTIFICIAL VENTILATION; AUTOPHAGY; AUTOSOMAL DISORDER; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FACE EDEMA; GENOTYPE PHENOTYPE CORRELATION; GLYCOGEN STORAGE DISEASE TYPE 2; HEART LEFT VENTRICLE MASS; HUMAN; HYDROLYSIS; IMMUNE STATUS; LOW CARBOHYDRATE DIET; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); MUSCLE BIOPSY; PATHOPHYSIOLOGY; PROGNOSIS; PRURITUS; RESPIRATORY FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING;

ALPHA-GLUCOSIDASES; ANIMALS; ENZYME REPLACEMENT THERAPY; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MUSCLE, SKELETAL;

EID: 84857628669     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0236-5     Document Type: Article

References (53)

1. C Angelini AG Engel 1973 Subcellular distribution of acid and neutral alpha-glucosidases in normal, acid maltase deficient, and myophosphorylase deficient human skeletal muscle Arch Biochem Biophys 156 350 355 4730478 10.1016/0003-9861(73)90374-3 1:CAS:528:DyaE3sXhsFOjtrg%3D
2. Hirschhorn R, Reuser, AJ. Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency. In: CR Scriver BA, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389-420
3. AT van der Ploeg AJ Reuser 2008 Pompe's disease Lancet 372 1342 1353 18929906 10.1016/S0140-6736(08)61555-X
4. B Bembi E Cerini C Danesino, et al. 2008 Diagnosis of glycogenosis type II Neurology 71 S4 S11 19047572 10.1212/WNL.0b013e31818da91e 1:CAS:528:DC%2BD1MXnsVOisw%3D%3D
5. P Laforet M Nicolino PB Eymard, et al. 2000 Juvenile and adult onset acid maltase deficiency in France: genotype-phenotype correlation Neurology 55 1122 1128 11071489 1:CAS:528:DC%2BD3cXotVOmt7g%3D
6. PS Kishnani WL Hwu H Mandel, et al. 2006 A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease J Pediatr 148 671 676 16737883 10.1016/j.jpeds.2005.11.033 (Pubitemid 43776899)
7. MLC Hagemans LP Winkel WC Hop, et al. 2005 Disease severity in children and adults with Pompe disease related to age and disease duration Neurology 64 2139 2214 15985590 10.1212/01.WNL.0000165979.46537.56 1:STN:280: DC%2BD2MzjsFSmtw%3D%3D (Pubitemid 40881011)
8. U Mellies F Stehling C Dohna-Schwake, et al. 2005 Respiratory failure in Pompe disease: treatment with noninvasive ventilation Neurology 64 1465 1467 15851748 10.1212/01.WNL.0000158682.85052.C0 1:STN:280:DC%2BD2M3hslCjsQ%3D%3D (Pubitemid 40570526)
9. ML Hagemans WJ Hop PA Van Doorn, et al. 2006 Course of disability and respiratory function in untreated lae onset Pompe disease Neurology 66 581 583 16505317 10.1212/01.wnl.0000198776.53007.2c 1:STN:280:DC%2BD287hvVGktQ%3D%3D (Pubitemid 43739893)
10. Angelini C, Semplicini C, Ravaglia S, and the Italian GSDII Group. Long-term follow-up effects on enzyme replacement treatment of adult form of acid maltase deficiency myopathy. Acta Myologica. 2011; in Press.
11. MLC Hagemans ACJW Janssens LPF Winkel, et al. 2004 Late-onset Pompe disease primarily affects quality of life in physical health domains Neurology 63 1688 1692 15534256 1:STN:280:DC%2BD2crmt1eguw%3D%3D (Pubitemid 39507589)
12. D Gungor JM de Vries WCJ Hop, et al. 2011 Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy Orphanet J Rare Dis 6 34 21631931 10.1186/1750-1172-6-34
13. Kanters TA, Hagemans ML, van der Beek NA, et al. Burden of illness of Pompe disease in patients only receiving supportive care. Inherit Metab Dis. 2011 Apr 16. [Epub ahead of print].
14. AC Nascimbeni M Fanin E Tasca C Angelini 2008 Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency Neurology 70 617 626 18285536 10.1212/01.wnl.0000299892.81127.8e 1:CAS:528: DC%2BD1cXhs1Kru74%3D (Pubitemid 351294639)
15. G Hug WK Schubert 1967 Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger J Cell Biol 35 C1 C6 5234586 10.1083/jcb.35.1.C1 1:STN:280:DyaF1c%2FlsFCksw%3D%3D
16. S Kornfeld 1992 Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors Annu Rev Biochem 61 307 330 1323236 10.1146/annurev.bi.61.070192.001515 1:CAS:528:DyaK38Xlt1Cmtb8%3D
17. Neufeld EF. Enzyme replacement therapy - a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 10.
18. M Rossi G Parenti R Della Casa, et al. 2007 Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells J Child Neurol 22 565 573 17690063 10.1177/0883073807302598 (Pubitemid 46951500)
19. H Van den Hout AJ Reuser AG Vulto, et al. 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 356 397 398 10972374 10.1016/S0140-6736(00)02533-2 (Pubitemid 30487498)
20. PS Kishnani D Corzo M Nicolino, et al. 2007 Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 68 99 109 17151339 10.1212/01.wnl.0000251268.41188.04 1:CAS:528:DC%2BD2sXosFSg (Pubitemid 46071892)
21. PS Kishnani M Nicolino T Voit, et al. 2006 Results from a phase II trial of Chinese hamster ovary cell-derived recombinant human acid a-glucosidase in infantile-onset Pompe disease J Pediatr 149 89 97 16860134 10.1016/j.jpeds.2006. 02.035 1:CAS:528:DC%2BD28XntFSns7c%3D (Pubitemid 44081924)
22. AT van der Ploeg 2010 Where do we stand in enzyme replacement therapy in Pompe's disease? Neuromuscul Disord 20 12 773 774 21094929 10.1016/j.nmd.2010. 09.011
23. B Bembi E Cerini C Danesino, et al. 2008 Management and treatment of glycogenosis type II Neurology 71 S12 S36 19047571 10.1212/WNL.0b013e31818da93f 1:CAS:528:DC%2BD1MXnsVOisA%3D%3D A task force of physicians reviewed the literature to provide guidelines for clinical and instrumental follow-up of GSDII patients, to monitor the natural course of the disease and to prevent and/or treat early any complication of this multisystemic disorder
24. AT van der Ploeg PR Clemens D Corzo, et al. 2010 A randomized study of alglucosidase alfa in late-onset Pompe's disease N Engl J Med 362 15 1396 1406 20393176 10.1056/NEJMoa0909859 This is the only double-blind randomized placebo-controlled study on efficacy of ERT in late onset patients. It demonstrated the efficacy of treatment in ameliorating motor and respiratory function
25. S Strothotte N Strigi-Pill B Grunert, et al. 2010 Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial J Neurol 257 91 97 19649685 10.1007/s00415-009-5275-3 1:CAS:528:DC%2BC3cXjsVShuw%3D%3D
26. B Bembi FE Pisa M Confalonieri, et al. 2010 Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II J Inherit Metab Dis 33 727 735 20838899 10.1007/s10545-010-9201-8 1:CAS:528:DC%2BC3cXhsVygsLrI
27. CI van Capelle LP Winkel ML Hagemans, et al. 2008 Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease Neuromuscul Disord 18 447 452 18508267 10.1016/j.nmd.2008.04.009
28. H Kobayashi Y Shimada M Ikegami, et al. 2010 Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case Mol Genet Metab 100 14 19 20202878 10.1016/j.ymgme.2010.01.015 1:CAS:528:DC%2BC3cXks1Wju7o%3D
29. S Ravaglia A Carlucci C Danesino 2010 Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: the two sides of low BMI Mol Genet Metab 100 388 20472481 10.1016/j.ymgme.2010.04.005 1:CAS:528: DC%2BC3cXovFymt7o%3D
30. D Orlikowski N Pellegrini H Prigent, et al. 2011 Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease Neuromuscul Disord 21 477 482 21550241 10.1016/j.nmd.2011.04. 001
31. MR Drost G Schaart P van Dijk, et al. 2008 Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease Muscle Nerve 37 2 251 255 17894362 10.1002/mus.20896 (Pubitemid 351214172)
32. MR Drost RP Hesselink CW Oomens GJ van der Vusse 2005 Effects of non contractile inclusions on mechanical performance of skeletal muscle J Biomech 38 1035 1043 15797585 10.1016/j.jbiomech.2004.05.040 (Pubitemid 40431444)
33. N Raben S Takikita MG Pittis, et al. 2007 Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand Autophagy 3 546 552 17592248 1:CAS:528:DC%2BD2sXhtlOhs7jF This paper reviews the importance of autophagy in pathophysiology of GSDII and reveals new mechanisms involved in the disease (Pubitemid 350060050)
34. BL Thurberg C Lynch Maloney C Vaccaro, et al. 2006 Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease Lab Invest 86 1208 1220 17075580 10.1038/labinvest.3700484 1:CAS:528:DC%2BD28Xht1akurzE (Pubitemid 44789911)
35. N Raben E Ralston YH Chien, et al. 2010 Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy Mol Genet Metab 101 324 331 20801068 10.1016/j.ymgme.2010.08.001 1:CAS:528:DC%2BC3cXhsVGnsbbP
36. N Raben C Schreiner R Baum, et al. 2010 Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease Autophagy 6 1078 1089 20861693 10.4161/auto.6.8.13378 1:CAS:528:DC%2BC3cXhs1WltrjJ
37. T Fukuda A Roberts M Ahearn, et al. 2006 Autophagy and lysosomes in Pompe disease Autophagy. 2 318 320 16874053 1:CAS:528:DC%2BD28XhtVGisbvK (Pubitemid 44342381)
38. S Zampieri E Buratti S Dominissini, et al. 2011 Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes Eur J Hum Genet 19 422 431 21179066 10.1038/ejhg.2010.188 1:CAS:528:DC%2BC3MXjsVCrs7o%3D
39. LH Hoefsloot M Hoogeveen-Westerveld AJ Reuser BA Oostra 1990 Characterization of the human lysosomal alpha-glucosidase gene Biochem J 272 493 497 2268276 1:CAS:528:DyaK3MXhs1ak
40. PS Kishnani PC Goldenberg SL DeArmey, et al. 2010 Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol Genet Metab 99 26 33 19775921 10.1016/j.ymgme.2009.08.003 1:CAS:528:DC%2BD1MXhsFGgtb7I
41. JM de Vries NA van der Beek MA Kroos, et al. 2010 High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa Mol Genet Metab 101 338 345 20826098 10.1016/j.ymgme.2010.08.009
42. SG Banugaria SN Prater YK Ng, et al. 2011 The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease Genet Med 13 729 736 21637107 10.1097/GIM. 0b013e3182174703 1:CAS:528:DC%2BC3MXpvVCjurk%3D
43. A Joseph K Munroe M Housman, et al. 2008 Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model Clin Exp Immunol 152 138 146 18307520 10.1111/j.1365-2249.2008.03602.x 1:CAS:528:DC%2BD1cXkvFamtbk%3D (Pubitemid 351347554)
44. NJ Mendelsohn YH Messinger AS Rosenberg PS Kishnani 2009 Elimination of antibodies to recombinant enzyme in Pompe's disease N Engl J Med 360 194 195 19129538 10.1056/NEJMc0806809 1:CAS:528:DC%2BD1MXnt1entg%3D%3D
45. DD Koeberl PS Kishnani 2009 Immunomodulatory gene therapy in lysosomal storage disorders Curr Gene Ther. 9 6 503 510 19807648 10.2174/ 156652309790031094 1:CAS:528:DC%2BC3cXhslals7k%3D
46. JP Little SM Phillips 2009 Resistance exercise and nutrition to counteract muscle wasting Appl Physiol Nutr Metab 34 5 817 828 19935843 10.1139/H09-093
47. AE Slonim L Bulone T Goldberg, et al. 2007 Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy Muscle Nerve 35 70 77 17022069 10.1002/mus.20665 1:CAS:528:DC%2BD2sXhsVOntL8%3D (Pubitemid 46052651)
48. Terzis G, Dimopoulos F, Papadimas GK, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 May 19. [Epub ahead of print].
49. Levenson D. Late onset Pompe disease revealed by newborn screening. Am J Med Genet A. 2011;155A(5).
50. YH Chien NC Lee HJ Huang, et al. 2011 Later-onset pompe disease: early detection and early treatment initiation enabled by newborn screening J Pediatr 158 1023 1027 21232767 10.1016/j.jpeds.2010.11.053 This paper discusses the importance of early diagnosis with newborn screening in metabolic myopathies such as GSDII, which may change more significantly the natural course of the disease
51. Y Zhu JL Jiang NK Gumlaw, et al. 2009 Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease Mol Ther 17 954 963 19277015 10.1038/mt.2009.37 1:CAS:528:DC%2BD1MXivVKmsrc%3D
52. JJ Flanagan B Rossi K Tang, et al. 2009 The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase Hum Mutat 30 1683 1692 19862843 10.1002/humu.21121 1:CAS:528:DC%2BC3cXkvFOmtw%3D%3D
53. G Parenti 2009 Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics EMBO Mol Med 1 268 279 20049730 10.1002/emmm.200900036 1:CAS:528:DC%2BD1MXht1CjurrF